NG

Ngl Fine Chem LtdNSE NGLFINE Stock Report

Last reporting period 31 Mar, 2024

Updated 07 Nov, 2024

Last price

Market cap $B

0.151

Micro

Exchange

XNSE - National Stock Exchange Of India

NGLFINE.NS Stock Analysis

NG

Uncovered

Ngl Fine Chem Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

54/100

Moderate score

Market cap $B

0.151

Dividend yield

0.15 %

Shares outstanding

6.178 B

NGL Fine-Chem Ltd. manufactures pharmaceuticals and intermediates for usage in veterinary and human health. The company is headquartered in Mumbai, Maharashtra and currently employs 343 full-time employees. The firm caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen, Flunixin Meglumine, and Imidocarb Dipropionate, among others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets.

View Section: Eyestock Rating